Moderna trims 2025 guidance after UK delivery delays
Q2 revenue ahead of forecasts but shares fall on reduced outlook
Moderna beat second‑quarter earnings expectations, powered by stronger COVID booster sales and cost cuts, but cut its full‑year guidance after reporting that key vaccine deliveries to the UK had been delayed into 2026, prompting a drop in its stock.
